The TSUBAKI and subsequent CARDINAL trials represent a shift toward "disease-modifying" treatments for CKD, moving beyond symptomatic management (like RAS inhibitors) to therapies that may actively improve renal function. While the FDA later reviewed Bardoxolone Methyl's New Drug Application for Alport syndrome based on these 2021 results, the focus remains on refining Nrf2 activators to ensure long-term cardiovascular safety.
Her 2021 debut was highly successful, leading her to quickly become a top-ranked actress on major Japanese distribution platforms like Common Criticisms Niche Appeal: tsubaki sannomiya 2021
Notable titles from her 2021 catalog included "A new employee and an unbeatable boss..." (January) and works featuring her "G-Cup" athletic build. The TSUBAKI and subsequent CARDINAL trials represent a
Sannomiya Tsubaki's First Best S1 Debut 1st Anniversary Mysterious Beautiful Girl's Latest 10 Titles 8 Hour Special , which curated her most impactful early work. Career Growth Sannomiya Tsubaki's First Best S1 Debut 1st Anniversary